Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupLymphoproliferative DisordersDiseaseMulticentric Castleman DiseaseSubgroupICD10D47.-MeSHCastleman DiseaseSequenceChemotherapyChemo-substanceDoxorubicin liposomalRituximabSiltuximabTocilizumabChemo-substanceDoxorubicin liposomalRituximabSiltuximabTocilizumabChemo-substanceDoxorubicin liposomalRituximabSiltuximabTocilizumabChemo-substanceDoxorubicin liposomalRituximabSiltuximabTocilizumabNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneNo. Substances14Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlDiarrheaEdemaEmetogenicityEmetogenicity (MASCC/ESMO)FatigueHyperhidrosisHypertensionInfectionsMucositisNeutropeniaPruritusPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorNishimoto NPria AUldrick TVan Rhee FDiseasemultizentrische Castleman-Krankheit, HIV-negative und HHV-8-negative Patienten, ECOG 0-2multizentrische Castleman-Krankheit, HIV-positive Patienten, ECOG 0-2multizentrische Castleman-Krankheit, HIV-positive und HHV-8-positive PatientenOriginDepartment of Oncology, The Chelsea and Westminster Hospital, London, United KingdomHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MDMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA Osaka University and Kyowakai Hospital, OsakaProtocols in Revision 4 protocols foundProtocols under revision.Rituximab 375 / Doxorubicin Liposomal 20, Multicentric Castleman disease (PID1959 V1.0)Rituximab 375, Multicentric Castleman disease (PID1952 V1.0)Siltuximab 11, Multicentric Castleman disease (PID352 V1.0)Tocilizumab 8, Multicentric Castleman disease (PID1953 V1.0)
